Aurora Cannabis Repurchases US$20 Million of Convertible Notes

Rhea-AI Summary

Aurora Cannabis has successfully repurchased approximately $25.3 million in convertible senior notes for $24.3 million in cash, achieving a 5.25% discount to par value. This strategic move aims to reduce debt and annual cash interest costs, with total savings now amounting to $9.5 million annually from Q3 2022 onwards. Aurora's current balance sheet showcases $455 million in cash, reinforcing its position as a leader in the cannabis industry, alongside a projected positive adjusted EBITDA by the first half of fiscal 2023.

Positive

• Debt repurchase of $25.3 million improves balance sheet and reduces cash interest expenses.
• Total annual savings of $9.5 million in interest costs bolster financial health.
• Strong cash position of $455 million enhances operational flexibility.

Negative

• None.

Aurora Further Strengthens Balance Sheet with Accretive Debt Reduction

EDMONTON, AB, June 3, 2022 /PRNewswire/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that it has repurchased an aggregate of approximately $25.3 million (US$20 million) principal amount of its convertible senior notes ("Notes") at a total cost, including accrued interest, of $24.3 million (US$19.2 million) in cash.

The purpose of the transaction, which represents a repurchase of a portion of the Notes at a 5.25% discount to par value, was to reduce the Company's debt and annual cash interest costs. Annual cash interest savings from the repurchases of Notes made from Q3 2022 onwards now total $9.5 million (US$7.5 million).

Aurora's balance sheet is among the strongest in the industry with approximately $455 million in cash inclusive of the transaction announced today, and the Company reiterates its expectation of achieving a positive Adjusted EBITDA run rate by the first half of fiscal 2023.

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering would be unlawful.

About Aurora
Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB" and is a constituent of the S&P/TSX Composite Index.

Forward Looking Statements
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the purpose of the debt repurchase and the Company's path and timing to achieve Adjusted EBITDA run rate.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated September 27, 2021 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-repurchases-us20-million-of-convertible-notes-301560693.html

SOURCE Aurora Cannabis Inc.

FAQ

What amount of convertible notes did Aurora Cannabis repurchase?

Aurora Cannabis repurchased approximately $25.3 million of its convertible senior notes.

How much did the debt repurchase cost Aurora Cannabis?

The total cost of the debt repurchase was $24.3 million in cash.

What are the expected annual cash interest savings from the notes repurchase?

Aurora expects annual cash interest savings of $9.5 million from the repurchase.

What is Aurora Cannabis's cash position after the repurchase?

Post-repurchase, Aurora Cannabis has approximately $455 million in cash.

When does Aurora expect to achieve a positive adjusted EBITDA?

Aurora anticipates achieving a positive adjusted EBITDA run rate by the first half of fiscal 2023.